Genomic Vision SA
PAR:GV
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
N/A
N/A
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Genomic Vision SA
Cash from Operating Activities
Genomic Vision SA
Cash from Operating Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Genomic Vision SA
PAR:GV
|
Cash from Operating Activities
-€5.4m
|
CAGR 3-Years
-18%
|
CAGR 5-Years
0%
|
CAGR 10-Years
N/A
|
|
|
Valneva SE
PAR:VLA
|
Cash from Operating Activities
-€18m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Nanobiotix SA
PAR:NANO
|
Cash from Operating Activities
-€31.2m
|
CAGR 3-Years
1%
|
CAGR 5-Years
1%
|
CAGR 10-Years
-10%
|
|
|
Inventiva SA
PAR:IVA
|
Cash from Operating Activities
-€162m
|
CAGR 3-Years
-37%
|
CAGR 5-Years
-53%
|
CAGR 10-Years
N/A
|
|
|
DBV Technologies SA
PAR:DBV
|
Cash from Operating Activities
-$87m
|
CAGR 3-Years
-116%
|
CAGR 5-Years
8%
|
CAGR 10-Years
-14%
|
|
|
Abivax SA
PAR:ABVX
|
Cash from Operating Activities
-€135m
|
CAGR 3-Years
-42%
|
CAGR 5-Years
-41%
|
CAGR 10-Years
N/A
|
|
Genomic Vision SA
Glance View
Génomic Vision SA is a molecular diagnostics and technology company, which develops and commercializes research tools and tests for the early detection of cancers and genetic diseases. The company is headquartered in Bagneux, Ile-De-France. The company went IPO on 2014-04-02. The company develops and commercializes single-DNA molecule diagnostic tests and research tools for life sciences, cancer and genetic diseases. The firm uses the molecular combining technique for the direct visualization of single DNA molecules to detect quantitative and qualitative changes in the genome landscape and establish their contribution to pathology. The company develops its products and services in three main markets: the medical diagnostic market focusing on DNA diagnostics (cancer genomics, genetic diseases); the pharmaceutical research and development market in the fields of genomics, to develop tests that can help physicians identify how patients are likely to respond to targeted therapies (personalized medicine, pharmacogenomics, cancer cell proliferation); and the academic laboratories research market, providing molecular combining tools for academic research in the field of cancer genetics, cytogenetics and DNA replication.
See Also
What is Genomic Vision SA's Cash from Operating Activities?
Cash from Operating Activities
-5.4m
EUR
Based on the financial report for Jun 30, 2023, Genomic Vision SA's Cash from Operating Activities amounts to -5.4m EUR.
What is Genomic Vision SA's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
0%
Over the last year, the Cash from Operating Activities growth was -29%. The average annual Cash from Operating Activities growth rates for Genomic Vision SA have been -18% over the past three years .